Infections and Acute Kidney Injury: A Global Perspective

Batte, Anthony; Shahrin, Lubaba; Claure-Del Granado, Rolando; Luyckx, Valerie A.; Conroy, Andrea L.

doi:10.1016/j.semnephrol.2023.151466

Cited by 9 publications

(1 citation statement)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An estimated 13.3 million AKI episodes occur every year worldwide, 85% of which occur in the least developed or developing countries, representing a serious financial problem for the majority of people who need it, with less than 10% of patients in these settings receiving kidney replacement therapy. Many people cannot afford kidney treatment at all, resulting in the death of over 1 million people annually from untreated kidney failure [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Biomarkers in Contrast-Induced Acute Kidney Injury: Towards A New Perspective

González-Nicolás,

González-Guerrero,

Goicoechea

et al. 2024

IJMS

View full text Add to dashboard Cite

Contrast-Induced Acute Kidney Injury (CI-AKI) remains a frequent iatrogenic condition since radiological procedures using intra-vascular iodinated contrast media (CM) are being widely administered for diagnostic and therapeutic purposes. Despite the improvement of the medical healthcare system worldwide, CI-AKI is still associated with direct short-term and indirect long-term outcomes including increased morbidity and mortality, especially in patients with underlying pre-existing renal function impairment, cardiovascular disease, or diabetes that could rapidly progress into Chronic Kidney Disease. Although the RIFLE (Risk, Injury, Failure, Loss, End-Stage Kidney Disease), AKIN (Acute Kidney Injury Network), and KDIGO (Kidney Disease Improving Global Outcomes) clinical criteria and recommendation guidelines are based on traditional “gold standard” biomarkers known as serum creatinine, glomerular filtration rate, and urinary output, new reliable serum and urinary biomarkers are still needed for an effective unified diagnostic strategy for AKI. Starting from previous and recent publications on the benefits and limitations of validated biomarkers responding to kidney injury, glomerular filtration, and inflammation among others, this review unravels the role of new emerging biomarkers used alone or in combination as reliable tools for early diagnosis and prognosis of CI-AKI, taking into account patients and procedures-risk factors towards a new clinical perspective.

show abstract

Section: Introductionmentioning

confidence: 99%

Biomarkers in Contrast-Induced Acute Kidney Injury: Towards A New Perspective

González-Nicolás,

González-Guerrero,

Goicoechea

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Acyl‐CoA Synthetase Long‐Chain Isoenzymes in Kidney Diseases: Mechanistic Insights and Therapeutic Implications

Mishra,

Shelke,

Gaikwad

2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Long‐chain acyl‐CoA synthetases (ACSLs) are pivotal enzymes in fatty acid metabolism, essential for maintaining cellular homeostasis and energy production. Recent research has uncovered their significant involvement in the pathophysiology of various kidney diseases, including acute kidney injury (AKI), chronic kidney disease (CKD), diabetic kidney disease (DKD), and renal cell carcinoma (RCC). While ACSL1, ACSL3, ACSL4, and ACSL5 have been extensively studied for their roles in processes such as ferroptosis, lipid peroxidation, renal fibrosis, epithelial‐mesenchymal transition, and tumor progression, the role of ACSL6 in kidney diseases remain largely unexplored. Notably, these isoenzymes exhibit distinct functions in different kidney diseases. Therefore, to provide a comprehensive understanding of their involvement, this review highlights the molecular pathways influenced by ACSLs and their roles in modulating cell death, inflammation, and fibrosis during kidney disease progression. By examining these mechanisms in detail, this review underscores the potential of ACSLs as biomarkers and therapeutic targets, advocating for further research to elucidate the precise roles of individual ACSL isoenzymes in kidney disease progression. Understanding these mechanisms opens new avenues for developing targeted interventions and improving therapeutic outcomes for patients with kidney diseases.

show abstract